Management of direct action oral anticoagulants in the peri-operative period and invasive techniques;Manejo de los anticoagulantes orales de acción directa en el período perioperatorio y técnicas invasivas

Revista Espanola de Anestesiologia y Reanimacion

Volumn 59, Issue 6, 2012, Pages 321-330

  Llau, J V ^a   Ferrandis, R ^a   Castillo, J ^b   de Andres J ^c   Gomar, C ^d   Gomez Luque A ^e   Hidalgo, F ^f   Torres, L M ^g  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Apixaban; Dabigatran; Haemorrhage; Oral anticoagulants; Peri operative; Rivaroxaban; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; DABIGATRAN; HEMOSTATIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MORPHOLINE DERIVATIVE; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG ADMINISTRATION; ELECTIVE SURGERY; EMERGENCY; HUMAN; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREMEDICATION; PROCEDURES; REGIONAL ANESTHESIA; RISK FACTOR; STANDARDS; THROMBOSIS;

ADMINISTRATION, ORAL; ANESTHESIA, CONDUCTION; ANTICOAGULANTS; ANTIDOTES; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; DRUG ADMINISTRATION SCHEDULE; ELECTIVE SURGICAL PROCEDURES; EMERGENCIES; FACTOR VIIA; FACTOR XA INHIBITORS; HEMOSTATICS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MORPHOLINES; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; PREMEDICATION; PYRAZOLES; PYRIDONES; RISK FACTORS; THIOPHENES; THROMBOSIS;

EID: 84868279909     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2012.01.007     Document Type: Article

References (42)

1. Weitz J.I., Hirsh J., Samama M.M. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(Suppl):234S-256S. American College of Chest Physicians.
2. Arcelus J.I., Cairols M., Granero X., Jiménez D., Llau J.V., Monreal M., et al. Nuevos anticoagulantes orales: una visión multidisciplinaria. Med Clin (Barc) 2009, 133:508-512.
3. Wittkowsky A.K. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolisys 2010, 29:182-191.
4. García D., Libby E., Crowter M.A. The new oral anticoagulants. Blood 2010, 115:15-20.
5. Rupprecht H.J., Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 2010, 70:2153-2170.
6. Eikelboom J.W., Weitz J.I. New anticoagulants. Circulation 2010, 121:1523-1532.
7. Eerenberg E.S., Kamphuisen P.W., Sijpens M.K., Meijens J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation 2011, 124:1573-1579.
8. Llau J.V., Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol 2009, 22:661-666.
9. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
10. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
11. Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramírez L.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl Med J 2010, 363:2487-2498.
12. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., et al. Apixaban in patients with atrial fibrilation. N Engl J Med 2011, 364:806-817.
13. Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrilation. N Engl J Med 2011, 365:981-992.
14. Alexander J.H., Lopes R.D., James S., Kilaru R., He Y., Mohan P., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708.
15. Información disponible en www.Clinicaltrials.gov.(identifier: NCT00643201).
16. Turpie A.G.G. Oral direct Xa factor inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007, 27:1238-1247.
17. Kakkar P., Watson T. Lip GYH. Rivaroxaban. Drugs Today 2007, 43:129-136.
18. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthropalsty. N Engl J Med 2008, 358:2765-2775.
19. Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
20. Información disponible en www.Clinicaltrials.gov (identifier: NCT00403767).
21. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. The EINSTEIN investigators.
22. Mega J.L., Braunwald E., Mohanavelu S., Burton P., Poulter R., Misselwitz F., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
23. Sanford M., Plosker G.L. Dabigatran etexilate. Drugs 2008, 68:1699-1709.
24. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008, 47:285-295.
25. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008, 36:386-399.
26. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., Van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
27. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., Van Dijk C.N., Frostick S.P., et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
28. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrilation. N Engl J Med 2009, 361:1139-1151.
29. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
30. Información disponible en www.Clinicaltrials.gov.(identifier: NCT00621855).
31. Gogarten W., Vandermeulen E., Van Aken H., Kozek S., Llau J.V., Samama M.C. Regional anaesthesia and antithrombotic agents: recommendations of European Society of Anaesthesiology. Eur J Anaesthesiol 2010, 27:999-1015.
32. Breivik H., Bang U., Jalonen J., Vigfussong, Alahuhta S., Lagerkranser M. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand 2010, 54:16-41.
33. Rosencher N., Bonnet M.-P., Sessler D.I. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 2007, 62:1154-1160.
34. Sié P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-Iia ou anti-Xa direct. Ann Fr Anesth Reanim 2011, 30:645-650.
35. Sierra P., Gómez-Luque A., Castillo J., Llau J.V. Guía de práctica clínica sobre el manejo de antiagregantes plaquetarios en cirugía no cardiaca (Sociedad Española de Anestesiología y Reanimación). Rev Esp Anestesiol Reanim 2011, (Supl 1):S1-S16.
36. Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Alperin J.L., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(Suppl):546S-592S. American College of Chest Physicians.
37. Van Ryn J., Stangier J., Haertter S., LiesenfeldKH, Wienen W., Feuring M., et al. Dabigatran etexilate- a novel, reversible, oral directthrombin inhibitor: interpretation of coagulation assays and reversal of anticaogulant activity. Thromb Haemost 2010, 103:1116-1127.
38. Dabigatran: Ficha técnica de las características del producto [consultado 30 Nov 2011]. Disponible en: http://www.pradaxa.es/web/pdf/FTPradaxaEuropaEspanol.pdf.
39. Información disponible en: www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf [consultado 30 Abr 2012).
40. Información disponible en: [consultado 28 Nov 2011]. http://www.healthcare.utah.edu/thrombosis/newagents.
41. Guidelines for the management of bleeding with dabigatran. Pharmaceutical management agency. New Zealand Government [consultado 28 Nov 2011]. Disponible en: http://www.pharmac.govt.nz/MedicineInformation/Dabigatran.
42. Pengo V., Crippa L., Falanga A., Finazzi G., Marongiu M., Palareti G., et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulantsin patients with atrial fibrilation. Thromb Haemost 2011, 106:868-876.